Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TuHURA BiosciencesSTU:PL3 -8.02%18 EV-to-OCF is -5.21 as of Aug. 18, 2026. GuruFocus rates STU:PL3 with a GF Score™ of 18/100. Among 1,409 Biotechnology companies, TuHURA Biosciences ranks better than 55.5% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, TuHURA Biosciences's Enterprise Value is €132.86 Mil.
TuHURA Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-25.50 Mil. Therefore, TuHURA Biosciences's EV-to-OCF for today is -5.21.
The historical rank and industry rank for TuHURA Biosciences's EV-to-OCF or its related term are showing as below:
STU:PL3'
s EV-to-OCF Range Over the Past 10 Years
Min: -5.18 Med: 0 Max: -5.18
Current: -5.18
During the past 5 years, the highest EV-to-OCF of TuHURA Biosciences was -5.18. The lowest was -5.18. And the median was .
STU:PL3's EV-to-OCF is ranked better than 55.5% of 1409
companies
in the Biotechnology industry
Industry Median: -3.6
vs STU:PL3: -5.18
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TuHURA Biosciences's PE Ratio (TTM) for today is calculated as:
TuHURA Biosciences's share price for today is €1.95.
TuHURA Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.464.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
TuHURA Biosciences EV-to-OCF Related Terms
TuHURA Biosciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for TuHURA Biosciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, TuHURA Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TuHURA Biosciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TuHURA Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where TuHURA Biosciences's EV-to-OCF falls into.
TuHURA Biosciences's current Enterprise Value is €132.86 Mil.
TuHURA Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-25.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TuHURA Biosciences (STU:PL3) has a EV-to-OCF of -5.21 as of Aug. 18, 2026. According to the industry distribution chart, TuHURA Biosciences ranks #627 out of 1409 companies in the Biotechnology industry, placing it in the top 44.5%.
Is TuHURA Biosciences' EV-to-OCF too high?
TuHURA Biosciences' current EV-to-OCF is -5.21. Based on the distribution chart, TuHURA Biosciences ranks #627 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, TuHURA Biosciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does TuHURA Biosciences' EV-to-OCF compare to CNTB and CUE?
According to the Biotechnology industry distribution chart, TuHURA Biosciences ranks #627 out of 1409 companies for EV-to-OCF. This puts TuHURA Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. TuHURA Biosciences's current EV-to-OCF is -5.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TuHURA Biosciences stock overvalued right now?
TuHURA Biosciences (STU:PL3) has a current EV-to-OCF of -5.21. The current EV-to-OCF is -5.21. TuHURA Biosciences' overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For TuHURA Biosciences (STU:PL3), the current EV-to-OCF is -5.21 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
18GF Score
Get the complete analysis for STU:PL3
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PL3 has been successfully added to your 
